linjc16/ctgov huggingface dataset:
CLINICAL OUTCOME OF ENDOTRACHEAL INTUBATION IN NON-TRAUMA PATIENTS

Study Overview
=================
Brief Summary
-----------------
The study will involve all adult patients visiting the Alexandria University main hospitals' Emergency department for reasons other than trauma that will require assisted ventilation via endotracheal intubation. Those pre-intubated or intubated post CPR will not be included. The main aim is to evaluate the clinical outcome (complications) of emergency endotracheal intubation and to correlate the incidence and nature of complications associated with tracheal intubations to demographic data and patient characteristics.

Official Title
-----------------
CLINICAL OUTCOME OF ENDOTRACHEAL INTUBATION IN NON-TRAUMA PATIENTS IN THE EMERGENCY DEPARTMENT OF ALEXANDRIA MAIN UNIVERSITY HOSPITAL

Conditions
-----------------
To Evaluate the Clinical Outcome (Complications) of Emergency Endotracheal Intubation in Non-traumatic Patients

Intervention / Treatment
-----------------
* Device: Macintosh Laryngoscope Vs Video Laryngoscope


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients of both sex with a life threatening impairment of the cardiovascular, respiratory or neurological system requiring emergency endotracheal intubation in the emergency department of Alexandria Main University Hospital. Exclusion Criteria: • Patients who are less than 18 years of age. Patients intubated out of the hospital. Trauma patients. Patients intubated for cardiac arrest. Failed intubation in the field

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Gender Based<br>Male patients will be compared to female patients with regards to incidence of complications | Device: Macintosh Laryngoscope Vs Video Laryngoscope<br>* Evaluate incidence of first trial success and complications<br>|
| Age Based<br>Various age groups will be evaluated to determine vulnerable age groups | Device: Macintosh Laryngoscope Vs Video Laryngoscope<br>* Evaluate incidence of first trial success and complications<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Major Adverse Events | Severe hypoxemia, Cardiac arrest, Cardiovascular collapse, Death | 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Moderate Complications | Cardiac arrhythmia, Esophageal intubation, Aspiration, Dental injury, Difficulty intubation, Agitation | 24 hours |
Better Classification of Respiratory Amyloidosis

Study Overview
=================
Brief Summary
-----------------
The B-AR project is based on a retrospective analysis of amyloidosis typing and the identification of their amylogenic protein.This work should be able to unite many clinicians, including pulmonologists and pathologists around a rare disease that still suffers from insufficient data.

Detailed Description
-----------------
The B-AR study will highlight the interest of proteomic analysis of amyloidosis compared to their identification by immunostaining. The objective is to reduce diagnostic wandering and to improve patient management. The typing of respiratory amyloidosis will allow a better characterization of the disease and thus, to propose a dedicated therapeutic management.

Official Title
-----------------
Towards a Better Classification of Respiratory Amyloidosis. Contribution of Proteomic Analysis Based on Tandem Mass Spectrometry

Conditions
-----------------
Amyloidosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patient > to 18 years with amyloidosis on a histological sample of the tracheobronchial or pulmonary tree. Exclusion Criteria: Subject receiving state medical aid Subject deprived of freedom, or under a legal protective measure (example: patients under guardianship or curators)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of cases with identification of the amylogenic protein in respiratory amyloidosis. | Identification of amylogenic protein by Proteomic Analysis Based on Tandem Mass Spectrometry on histological sample of the tracheobronchial or pulmonary tree. | 1 day (at inclusion) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Distribution and severity of amyloidosis | association between typing and respiratory involvement | 1 day (at inclusion) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
respiratory amyloidosis, proteomic analysis
A Web-based Calculator Predicts Heterogeneous Frailty Trajectories

Study Overview
=================
Brief Summary
-----------------
To explore the predictive factors of frailty trajectories and develop a web-based nomogram among gastric cancer survivors.

Detailed Description
-----------------
The aims of this study are to explore the predictive factors of frailty trajectories in gastric cancer patients more comprehensively based on the health ecology theory and to construct a clinically convenient web-based prediction calculator, so as to screen high-risk frailty elderly gastric cancer patients at an early stage in clinical practice, and thus to implement early interventions to improve the prognosis.

Official Title
-----------------
A Web-based Calculator Predicts Heterogeneous Frailty Trajectories Among Elderly Gastric Cancer Survivors

Conditions
-----------------
Gastric Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosed with gastric cancer by endoscopy or pathology; age ≥60 years old; radical gastrectomy was proposed; be able to communicate simply in writing and verbally. Exclusion Criteria: combined with other sites of malignant tumors; combined with severe heart, liver, lung, and renal insufficiency; recent using hormones, immunosuppressants; with physical disabilities.

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| frailty trajectories | Frailty was measured by Tilburg frailty indicator (TFI) scale at discharge, one month, three months, six months and twelve months after surgery. | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
gastric cancer
Clinical and Healthcare Outcomes From Real-World Use in the United States of a Companion AI During AF Ablation

Study Overview
=================
Brief Summary
-----------------
Observational, multi-center, clinical device registry for US patients with a primary goal to observe the clinical outcomes in patients who are mapped with Volta Medical's VX1 or AF-Explorer systems during AF ablation procedures.

Official Title
-----------------
Clinical and Healthcare Outcomes From Real-World Use in the United States of a Companion AI During AF Ablation

Conditions
-----------------
Atrial Fibrillation

Intervention / Treatment
-----------------
* Device: AF Ablation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients 21 years of age or older who is: indicated for AF ablation or Who has received an AF-ablation with the past 24 months where VX1 was used or Patients are receiving or received a catheter ablation procedure for AF according to current guidelines Patients must be able and willing to provide written informed consent to participate in the clinical trial Exclusion Criteria: Patients not indicated or were not indicated for catheter ablation according to current guidelines Patients with AF secondary to an obvious reversible cause Patients who are or may potentially be pregnant Enrollment in an investigational study evaluating another non-VX1 investigational device, biologic, or drug

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: AF Ablation|Percutaneous, catheter-based ablation of atrial fibrillation|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary Clinical Efficacy Outcome | Percentage of subjects free from clinically significant AF or atrial arrhythmia recurrences, after one or multiple ablation procedures, stratified by type of clinical workflow and ablation history. | 12 and 24 months |
Immune Profiling for Cancer Immunotherapy Response

Study Overview
=================
Brief Summary
-----------------
In patients clinically treated with FDA-approved immunotherapy the investigators will assess the predictive value of pre- and on-treatment 1) immune-methylation profiling across cancer types, and 2) immune-methylation profiling and cytokine profiling within cancer types.

Official Title
-----------------
Immune Profiling for Cancer Immunotherapy Response

Conditions
-----------------
Cancer, Tumor, Solid, Hematologic Malignancy, Blood Cancer

Intervention / Treatment
-----------------
* Diagnostic Test: Methylation Cytometry


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cancer patients receiving or will receive immunotherapy under FDA- approved indication (e.g. checkpoint inhibitor therapy with pembrolizumab, nivolumab, or ipilimumab, or cellular immunotherapy). Participants are eligible regardless of the type of prior therapy (i.e. prior immunotherapy treated participants can be included). Exclusion Criteria: Pregnant women/fetuses/neonates Prisoners Decision-impaired individuals

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Standard of Care Checkpoint<br>Patients receiving standard of care FDA approved immunotherapy | Diagnostic Test: Methylation Cytometry<br>* Assessment of the ability of Methylation Cytometry in pre-treatment peripheral blood and in repeated measures over the duration of treatment to predict treatment response or occurrence of adverse events.<br>|
| Bone Marrow Transplant<br>Patients undergoing transplant for hematologic malignancy | Diagnostic Test: Methylation Cytometry<br>* Assessment of the ability of Methylation Cytometry in pre-treatment peripheral blood and in repeated measures over the duration of treatment to predict treatment response or occurrence of adverse events.<br>|
| CAR T<br>Patients undergoing CAR T therapy | Diagnostic Test: Methylation Cytometry<br>* Assessment of the ability of Methylation Cytometry in pre-treatment peripheral blood and in repeated measures over the duration of treatment to predict treatment response or occurrence of adverse events.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Response to therapy | The investigators will employ iRECIST, and outcome criteria will be clinically evaluated and include the primary endpoints of progression (non-responders) or response, with patients followed up every month for 6 months (or until death, loss to follow-up, or withdrawal of consent), judged according to the objective response rate (ORR) assessed using iRECIST. | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Immunotherapy
Assessment of Admission to the ICU of Onco-hematological Patients.

Study Overview
=================
Brief Summary
-----------------
Multicenter, observational and prospective study.

Detailed Description
-----------------
The data collection period will include 6 consecutive months, starting from the date of acceptance or conformity of the CEIC. Or, until an adequate sample size is reached that guarantees the statistical relevance of said analysis. All patients will subsequently be followed up 3 months after discharge from the ICU.

Official Title
-----------------
Assessment of Admission to the ICU of Onco-hematological Patients. Income Patterns and Results.

Conditions
-----------------
Hematological Diseases, Critical Illness

Intervention / Treatment
-----------------
* Other: There is no intervention.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults Solid organ tumor or hematological malignancy, Exclusion Criteria: -under 18 years old

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients admitted to the ICU.<br> | Other: There is no intervention.<br>* There is no intervention in the study.<br>|
| Patients who are not admitted to the ICU.<br> | Other: There is no intervention.<br>* There is no intervention in the study.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hospital mortality. |  | During the 6 months of the study. |
Dentoskeletal Changes Expansion Using Invisalign Versus Conventional Expander

Study Overview
=================
Brief Summary
-----------------
Cbct evaluation of dentoskeletal changes after expansion using Invisalign versus conventional expander

Detailed Description
-----------------
Using cbct for evaluation of dentoskeletal changes after expansion using Invisalign versus conventional expander hyrax

Official Title
-----------------
Evaluation of Dentoskeletal Changes After Expansion Using Invisalign Versus Conventional Expander Prospective Clinical Study

Conditions
-----------------
Expansion of Maxillary Arch, Maxillary Hypoplasia

Intervention / Treatment
-----------------
* Device: Invisalign
* Device: Conventional expander


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age (12-16) Good oral hygiene Constricted maxilla or moderate crowding Exclusion Criteria: Patient receive drugs Periodontal diseas Past Orthodontic treatment

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Expansion of maxillary arch by 2 different techniques including conventional expander in one group compared with expansion with clear aligner.
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Conventional expander<br>Expansion using conventional orthodontic expander(hyrax) | Device: Conventional expander<br>* conventional expander<br>|
| Experimental: Invisalign<br>Expansion with Invisalign appliance | Device: Invisalign<br>* Expansion using Invisalign versus conventional expander<br>* Other names: Hyrax;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Linear amount of midpalatal Suture opening | Apperance of Distema , calculate the amount of general space | 4 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Expander, Hyrax, Invisalign
Prospective Cohort of Perioperative Results

Study Overview
=================
Brief Summary
-----------------
Perioperative online register of the care process and outcomes. Observational prospective cohort.

Detailed Description
-----------------
Center are invited to join the perioperative register where they input anonymized data about the surgical process and outcome.

Official Title
-----------------
My Journey - Prospective Cohort of Perioperative Results

Conditions
-----------------
Perioperative/Postoperative Complications

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing surgery Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: No intervention|No intervention|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Perioperative International Register | Collaborative register of preoperative variables | 20 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Periopererative, Enhanced Recovery
Overal Survival After TAVI According to Sarcopenia

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to compare the overal survival after transcatheter aortic valve implantation (TAVI) according to sarcopenia status evaluated from preprocedural CT scans. The main question it aims to answer is: • Is CT evaluated sarcopenia an independent predictor of overal survival after TAVI?

Detailed Description
-----------------
The patients suffering from aortic valve stenosis, that are not eligible for cardiosurgery were indicated to miniinvasive transcatheter aortic valve implantation (TAVI). The follow up of 930 patients were done in time interval from 1 to 11 years. In every patient the preprocedural CT scans were done. From these CT scans the L3 cross sections will be used for sarcopenia evaluation. Then we will statisticaly evaluate the overal survival after TAVI procedure in the relation with sarcopenia status. We will answer the main question: Is CT evaluated sarcopenia an independent predictor of overal survival after TAVI?

Official Title
-----------------
CT Evaluated Sarcopenia Independently Predicts the Overal Survival After Transcatheter Aortic Valve Implantation

Conditions
-----------------
Sarcopenia, Aortic Valve Stenosis

Intervention / Treatment
-----------------
* Diagnostic Test: CT evaluated sarcopenia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients udergone TAVI procedure Exclusion Criteria: patients with incomplete TAVI procedure, patients without clinical follow up
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: CT evaluated sarcopenia|At L3 level of CT scan we will measure the area and density of muscles and fat tissue. We devided the patients to sarcopenia and non-sarcopenia groups according to these values.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overal survival | Time from the TAVI procedure to death | 11 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sarcopenia, survival, TAVI
A Retrospective Analysis: Whether Five Factors Affect PFS in Patients With Locally Advanced Cervical Cancer

Study Overview
=================
Brief Summary
-----------------
In previous studies, the investigators found that five factors were effective in predicting the probability of locally advanced cervical cancer with para-aortic lymph node metastasis.A retrospective study was conducted to explore the influence of 5 factors on PFS in patients with locally advanced cervical cancer receiving radiotherapy and chemotherapy.

Detailed Description
-----------------
In previous studies, the investigators found that five factors were effective in predicting the probability of locally advanced cervical cancer with para-aortic lymph node metastasis.5 factors included positive iliac lymph nodes, histological type, tumor size, positive pelvic lymph nodes on both sides, and maximum lymph node diameter greater than 1cm. Different factors give different scores.If the score is higher than 3, the probability of retroperitoneal lymph node metastasis in patients with locally advanced cervical cancer is significantly increased, and the prognosis of patients is affected. Patients with locally advanced cervix receiving radical radiotherapy were scored based on 5 factors.Patients with scores greater than or equal to 3 points were compared with patients with scores less than 3 points.

Official Title
-----------------
A Retrospective Analysis: Whether Five Factors Affect PFS in Patients With Locally Advanced Cervical Cancer

Conditions
-----------------
Locally Advanced Cervical Cancer, Radiotherapy

Participation Criteria
=================
Eligibility Criteria
-----------------
Locally advanced cervical cancer patients receiving radiotherapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Scores greater than or equal to 3 in patients with locally advanced cervical cancer<br>Scores greater than or equal to 3 in patients with locally advanced cervical cancer | |
| Patients with locally advanced cervical cancer scored less than 3 points<br>Patients receiving radiotherapy for locally advanced cervical cancer were scored according to five factors, with a score of less than 3 | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression Free Survival（PFS） | Whether there are differences in PFS between the two groups | 3 months |